We have located links that may give you full text access.
Lapatinib induced Annexin A6 up-regulation as an adaptive response of triple negative breast cancer cells to EGFR tyrosine kinase inhibitors.
Carcinogenesis 2018 December 28
The epidermal growth factor receptor (1) is a major oncogene in triple negative breast cancer (TNBC), but the use of EGFR targeted tyrosine kinase inhibitors (TKI) and therapeutic monoclonal antibodies is associated with poor response and acquired resistance. Understanding the basis for the acquired resistance to these drugs and identifying biomarkers to monitor the ensuing resistance remains a major challenge. We previously showed that reduced expression of annexin A6 (AnxA6), a calcium dependent membrane binding tumor suppressor, not only promoted the internalization and degradation of activated EGFR but also sensitized TNBC cells to EGFR TKIs. Here, we demonstrate that prolong (>3 days) treatment of AnxA6-low TNBC cells with lapatinib led to AnxA6 up-regulation and accumulation of cholesterol in late endosomes. Basal ERK1/2 activation was EGFR-independent and significantly higher in lapatinib resistant MDA-MB-468 (LAP-R) cells. These cells were more sensitive to cholesterol depletion than untreated control cells. Inhibition of lapatinib-induced up-regulation of AnxA6 by RNA interference (A6sh) or withdrawal lapatinib from LAP-R cells not only reversed the accumulation of cholesterol in late endosomes but also led to enrichment of plasma membranes with cholesterol, restored EGFR-dependent activation of ERK1/2 and sensitized the cells to lapatinib. These data suggest that lapatinib induced AnxA6 expression and accumulation of cholesterol in late endosomes constitute an adaptive mechanism for EGFR expressing TNBC cells to overcome prolong treatment with EGFR-targeted TKIs, and can be exploited as an option to inhibit and/or monitor the frequently observed acquired resistance to these drugs.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app